115 results
S-3ASR
EX-5.1
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in this letter.
We have not been responsible for investigating or verifying the accuracy of the facts or the reasonableness of any statement of opinion … not been responsible for investigation or verification of statements of fact (including statements as to foreign law) or the reasonableness of any
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
is solely responsible for, and has sole decision-making authority with respect to, at its own expense, the exploitation of Binder Licensed Products.
We … are solely responsible, at our expense, for developing the products that use the in-licensed patent rights and obtaining all regulatory approvals
10-K
2023 FY
EX-31.1
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
in this report;
The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
10-K
2023 FY
EX-31.2
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
in this report;
The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
in such country or jurisdiction, including in the US, an EUA. 1.182 “Regulatory Authority” means any governmental agency or authority responsible … and conditions of this Agreement; (c) BioNTech shall remain responsible for the performance of all of its Sublicensees to the same extent as if such activities
424B5
xnb 62ir5c4ou
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-5.1
9ez6pzt gte
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
aml58ui
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.2
fgx5osb pw
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.1
g1u1g2alxqmh
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
a4hwl11yfabc8 4qk79a
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.10
01j7ba
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.7
9xctiqubi dzt7ad
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.9
heemblj562ju1svdce
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-5.1
kw1ohd ls
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.1
36ohi4ij
22 Dec 23
Departure of Directors or Certain Officers
8:24am
10-Q
EX-10.2
9pu9h
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-31.1
ohvzlwbb8 3ojhwvx
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-31.2
w5ewe1f34
9 Nov 23
Quarterly report
4:18pm
S-8
EX-5.1
q09xbr0b
3 Nov 23
Registration of securities for employees
4:02pm